Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Diskapi Teaching and Research Hospital, Ankara, Altindag, Turkey
Merck Sharp & Dohme GmbH, Haar, Germany
MSD Italia S.r.l., Rome, Italy
Department of anesthesia and department of minimal invasive gynecology, Aleris-Hamlet, Søborg, Denmark
Medical University of Vienna, Department of Emergency Medicine, Vienna, Austria
Faculty hospital Brno, Brno, Jihomoravský Kraj, Czech Republic
Faculty Hospital Olomouc, Olomouc, Olomoucký kraj, Czech Republic
Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
Medical University Vienna, Vienna, Austria
Department of Anesthesiology, Surgical Sciences and Intensive Care Medicine, Karolinska University Hospital, Stockholm, Sweden
Azienda Ospedaliera di Padova, Padova, Italy
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.